7 results about "Plasma cholesterol" patented technology

Disclosed are synthetic apolipoprotein E-mimicking peptides, derivatives thereof, and related peptides, which are useful as therapeutic agents for reducing plasma cholesterol; synthetic methods of making the peptides; pharmaceutical compositions comprising the peptides, and methods of treating lipid and metabolic disorders using the disclosed synthetic apolipoprotein E-mimicking peptides and compositions thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention discloses an application of Synaptamide in the treatment of hyperlipemia, and relates to a medicine for treating hyperlipemia. In-vivo experiments are carried out in a hyperlipidemia mouse model fed with high-fat diet, and after treatment with Synaptamide, the content of plasma triglyceride is remarkably reduced, and the content of plasma cholesterol is remarkably reduced. Therefore, Synaptamide can be used as a medicine for treating hyperlipemia, it is found for the first time that Synaptamide can effectively reduce the content of triglyceride and cholesterol in blood, and the medicine can effectively prevent and control hyperlipemia so as to reduce the incidence rate of ASCVD, so that a new intervention means is provided for prevention and control of atherosclerosis and related cardiovascular and cerebrovascular diseases.

The present invention relates to compounds of Table 1, which are encompassed by Formula I and / or Formula II, Ill, IV, V, or VI, and pharmaceutically acceptable salts, solvates or compositions thereof. Compounds of Table 1 are PCSK9 interacting small molecules that modulate PCSK9 activity and significantly increase low density lipoprotein receptor expression and activity, lower total circulating cholesterol and are useful for treating and delaying the onset of diseases that are associated with elevated cholesterol.

The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amount of a pharmaceutically acceptable salt of fluvastatin; hydroxypropyl methyl cellulose; and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000 for the reduction of plasma cholesterol levels.

The present disclosure includes compositions and methods for treating cardiovascular disease (CVD) (e.g., cholesterol related disorders, or diseases caused or characterized by increased levels of plasma triglycerides, plasma cholesterol, or serum C-reactive protein), or symptoms thereof. The disclosure also includes compositions and methods for lowering plasma triglycerides in a subject, lowering plasma cholesterol levels in a subject, and lowering serum C-reactive protein levels in a subject.

The present disclosure provides use of cholesin in modulating cholesterol homeostasis and a composition comprising cholesin, a nucleic acid encoding cholesin, an expression vector comprising the nucleic acid, or an agent for enhancing the expression or activity of endogenous cholesin protein in a subject. Specifically, the present disclosure relates to a method for treating or preventing a disease associated with an elevated plasma cholesterol level in a subject. The method comprises: administering to the subject an effective amount of cholesin, a nucleic acid encoding cholesin, or an expression vector comprising the nucleic acid, or enhancing the expression or activity of endogenous cholesin protein in the subject.

The present invention relates to a composition comprising Rhodospirillum rubrum cells for use in a method for inhibiting the uptake of cholesterol from the intestine in a human subject, such that the plasma LDL-cholesterol level in said human subject is lowered and concentrations of blood proteins relating to kidney function, liver function and / or heart function are essentially unaltered. In addition, the invention relates to a non-therapeutic method of lowering plasma LDL-cholesterol level in a subject, the method comprising administering to the subject a composition comprising Rhodospirillum rubrum cells, wherein lowering of the plasma LDL-cholesterol level is the inhibition of the uptake of cholesterol from the intestine in said human subject. Furthermore, the invention relates to a food product, a feed product, a food stuff and a food supplement comprising Rhodospirillum rubrum cells and having plasma LDL-cholesterol level lowering properties relating to intestinal cholesterol uptake inhibitory properties.